当前位置: X-MOL 学术BMC Cancer › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Application of CD54 in diagnosing bone marrow involvement by using flow cytometry in patients with diffuse large B-cell lymphoma
BMC Cancer ( IF 3.4 ) Pub Date : 2021-09-09 , DOI: 10.1186/s12885-021-08753-0
Wei Wang 1 , Yan Li 2 , Xavier Rivera Rivera 1 , Linjun Zhao 3 , Di Mei 3 , Wenqing Hu 2 , Bin Jiang 2
Affiliation  

Flow cytometry plays a key role in detecting bone marrow (BM) involvement in patients with diffuse large B-cell lymphoma (DLBCL). To improve its detection sensitivity, we need to explore novel markers. In this study, we detected the expression CD54 on lymphoma cells in BM specimens from DLBCL patients and clarified its diagnostic significance in BM involvement by DLBCL. We collected BM specimens from 76 patients with DLBCL (germinal center B-cell (GCB) = 25, non-GCB = 51) and 10 control patients without lymphoma. We detected and compared the expression of CD54 on lymphoma cells and normal mature B cells by using 10-color panels. Normal plasma cells expressed a higher level of CD54 as compared with hematogones (p < 0.05) and normal mature B cells (p < 0.05). Among 76 patients, 23 of them (GCB = 12, non-GCB = 11) had BM involvement. Lymphoma B cells from 12 cases (GBC = 4, non-GCB = 8) expressed a higher level of CD54 compared to normal mature B cells (p < 0.05). Additionally, lymphoma cells of the non-GCB subtype frequently expressed a higher level of CD54 in comparison to the GCB subtype (p < 0.05). And the high expression of CD54 was not related to plasmacytoid differentiation. Aberrant expression of CD54 on lymphoma cells is frequently seen in patients’ BM specimens involved by DLBCL, especially in the non-GCB subtype. CD54 could be used as a new marker to gate on lymphoma cells and improve the detection sensitivity of BM involvement in patients with DLBCL.

中文翻译:

CD54在流式细胞术诊断弥漫性大B细胞淋巴瘤患者骨髓受累中的应用

流式细胞术在检测弥漫性大 B 细胞淋巴瘤 (DLBCL) 患者的骨髓 (BM) 受累方面起着关键作用。为了提高其检测灵敏度,我们需要探索新的标记。在本研究中,我们检测了 DLBCL 患者骨髓标本中淋巴瘤细胞上 CD54 的表达,并阐明了其在 DLBCL 受累骨髓中的诊断意义。我们收集了 76 名 DLBCL 患者(生发中心 B 细胞 (GCB) = 25,非 GCB = 51)和 10 名无淋巴瘤对照患者的 BM 标本。我们使用 10 色面板检测并比较了 CD54 在淋巴瘤细胞和正常成熟 B 细胞上的表达。与血细胞生成素 (p < 0.05) 和正常成熟 B 细胞 (p < 0.05) 相比,正常浆细胞表达更高水平的 CD54。在 76 名患者中,其中 23 名(GCB = 12,非 GCB = 11)有 BM 受累。与正常成熟 B 细胞相比,来自 12 个病例(GBC = 4,非 GCB = 8)的淋巴瘤 B 细胞表达更高水平的 CD54(p < 0.05)。此外,与 GCB 亚型相比,非 GCB 亚型的淋巴瘤细胞经常表达更高水平的 CD54 (p < 0.05)。并且CD54的高表达与浆细胞样分化无关。淋巴瘤细胞上 CD54 的异常表达在 DLBCL 涉及的患者 BM 标本中经常看到,尤其是在非 GCB 亚型中。CD54可作为一种新的标志物来对淋巴瘤细胞进行门控,提高DLBCL患者BM受累的检测灵敏度。与 GCB 亚型相比,非 GCB 亚型的淋巴瘤细胞经常表达更高水平的 CD54 (p < 0.05)。并且CD54的高表达与浆细胞样分化无关。淋巴瘤细胞上 CD54 的异常表达在 DLBCL 涉及的患者 BM 标本中经常看到,尤其是在非 GCB 亚型中。CD54可作为一种新的标志物来对淋巴瘤细胞进行门控,提高DLBCL患者BM受累的检测灵敏度。与 GCB 亚型相比,非 GCB 亚型的淋巴瘤细胞经常表达更高水平的 CD54 (p < 0.05)。并且CD54的高表达与浆细胞样分化无关。淋巴瘤细胞上 CD54 的异常表达在 DLBCL 涉及的患者 BM 标本中经常看到,尤其是在非 GCB 亚型中。CD54可作为一种新的标志物来对淋巴瘤细胞进行门控,提高DLBCL患者BM受累的检测灵敏度。
更新日期:2021-09-10
down
wechat
bug